Device Trial Radar · NCT04624698
iStent Inject New Enrollment Post-Approval Study
Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
358
Planned (sponsor's estimate)
Start
Sep 22, 2020
Primary completion
May 2026
Study completion May 2026
Sponsor
- Lead sponsor
- Glaukos CorporationPublic (GKOS)
- Sponsor type
- Industry
- First posted
- Nov 12, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.
Conditions
- Glaucoma, Open-Angle
- Glaucoma
Interventions
iStent Inject ImplantationDevice
Subjects will be implanted with the iStent Injection Micro-Bypass device
Primary outcomes
What the sponsor says the trial is designed to measure.
- iStent inject placement and stabilityTime frame: 36 Months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Eye Doctors of Arizona, PLLC
Phoenix, Arizona
Wolstan and Goldberg Eye Associates
Torrance, California
Glaucoma Associates of Texas
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.